Diaz, Miguel F.
Horton, Paulina D.
Kumar, Akshita
Livingston, Megan
Mohammadalipour, Amina
Xue, Hasen
Skibber, Max A.
Ewere, Adesuwa
Toledano Furman, Naama E.
Aroom, Kevin R.
Zhang, Songlin
Gill, Brijesh S.
Cox, Charles S. Jr.
Wenzel, Pamela L.
Funding for this research was provided by:
State of Texas Emerging Technology Fund
National Institutes of Health (R01DK111599)
American Society of Hematology (Scholar Award)
Cancer Prevention and Research Institute of Texas (RP110776)
Mission Connect: a Program of the TIRR Foundation (014-121)
Article History
Received: 23 January 2020
Accepted: 10 June 2020
First Online: 1 July 2020
Competing interests
: C.S.C. serves on the Scientific Advisory Board for CBR, Inc. and conducts sponsored research with Athersys, Inc., Celgene Therapeutics, Inc., and CBR. K.R.A, B.S.G., C.S.C., and P.L.W. are inventors on a patent for conditioning of stem and progenitor cells for cellular therapy (U.S. Patent US20180187141A1). All other authors declare no conflict of interest.